OCL

LOE Approaching

polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate

Pfizer

NDAORALSOLUTION

Approved

Apr 1986

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

Clinical Trials (5)

NCT07175415Phase 1/2Not Yet Recruiting

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Started Oct 2026

42 enrolled

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more

NCT07471841Phase 2Not Yet Recruiting

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Started May 2026

25 enrolled

IDH1 MutationRelapsed / Refractory AML

NCT06782542Phase 2Recruiting

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Started May 2026

16 enrolled

Acute Myeloid LeukemiaIDH1 Mutation

NCT07341191Phase 2Not Yet Recruiting

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Started Mar 2026

40 enrolled

Mantle Cell Lymphoma

NCT07387471Phase 2Recruiting

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Started Mar 2026

14 enrolled

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma

Company

External Resources

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers